ERBB2 and breast carcinoma: The presence of one or a combination of the estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER2) render one group of breast cancers susceptible to hormonal/HER2 targeted therapy [32].